ACCELERATING RESEARCH BREAKTHROUGHS WITH DECENTRALIZED Trials
By leveraging a combination of token governance, special jurisdictions, and special IRB oversight, we streamline regulatory pathways and accelerate clinical translation. Our mission is to replace anecdotal evidence with high-quality clinical-grade data and expand patient access to cutting-edge regenerative treatments.
How it works
Tokenized Governance
Community and expert stakeholders collectively approve trial designs, ensuring accountability and rigor. Each stage of trial approval is executed via token governance, ensuring transparency and eliminating unnecessary delays.
dIRB
dIRB (decentralized Institutional Review Board) replaces slow, bureaucratic decision-making with a distributed network of global experts who review and approve clinical trials with transparency, significantly reducing approval times. By leveraging blockchain for transparent governance and decision tracking, it ensures accountability and prevents conflicts of interest, making the process both faster and more transparent than traditional centralized boards.
Special Jurisdictions
Special jurisdictions are regions with flexible regulatory frameworks that enable faster approval and clinical deployment of innovative therapies. Unlike traditional agencies like the FDA, these jurisdictions allow early patient access, real-world data collection, and streamlined trial approvals while maintaining safety oversight. StemDAO partners with these forward-thinking regions to accelerate regenerative medicine and bring cutting-edge stem cell and EV therapies to patients sooner.
Partner Clinics
We are collaborating with world-class clinics to facilitate experimental treatments and real-world validation of our therapies under the StemDAO framework.
